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T
he role of vitamin C in the 
prevention and treatment 
of the common cold has 
been a subject of controversy for at 
least 60 years. Public interest in the 
subject, stimulated originally by the 
vigorous advocacy of Nobel laureate 
Linus Pauling during the 1970s [1], 
continues to be high. We have recently 
updated the Cochrane Review [2] on 
this topic (Text S1), incorporating 55 
comparative studies that have been 
carried out over a period of 65 years.
The Updated Review
We sought to discover whether vitamin 
C in doses of 200 mg or more daily 
(Figure 1) reduces the incidence, 
duration, or severity of the common 
cold when used either as continuous 
prophylaxis or after the onset of cold 
symptoms. Criteria for inclusion were 
placebo-controlled trials to prevent 
or treat the common cold using oral 
doses of vitamin C of 200 mg/day or 
more. Literature from 1940 to 2004 was 
methodically screened. 
An overview of the results of the 
three meta-analyses is shown in Table 
1. Incidence was not altered in the 
subgroup of 23 community studies 
where prophylactic doses as high as 2 
g daily were used. But a subgroup of 
six studies of marathon runners, skiers, 
and soldiers exposed to signiﬁ  cant cold 
and/or physical stress experienced, on 
average, 50% reduction in common 
cold incidence.
Duration of cold episodes that 
occurred during prophylaxis was 
signiﬁ  cantly reduced in both 
children and adults. For children this 
represented an average reduction of 
14% in symptom days, while in adults 
the reduction was 8%.  
For the seven trials that evaluated the 
therapeutic impact of vitamin C used at 
the onset of symptoms (all in adults), 
beneﬁ  ts were not observed for duration 
of episodes, 
although one of the 
large trials recorded 
a statistically 
signiﬁ  cant 
reduction in the 
duration of colds 
among participants 
administered a 
single vitamin C 
dose of 8 g on the 
day of symptom 
onset [3].
Implications of 
the Review
The lack of effect of 
prophylactic vitamin 
C supplementation 
on the incidence 
of common cold in 
normal populations 
throws doubt on 
the utility of this 
wide practice. 
The clinical signiﬁ  cance of the minor 
reduction in duration of common 
cold episodes experienced during 
prophylaxis is questionable, although 
the consistency of these ﬁ  ndings points 
to a genuine biological effect.  
In special circumstances, where 
people used prophylaxis prior to 
extreme physical exertion and/or 
exposure to signiﬁ  cant cold stress, 
the collective evidence indicates that 
vitamin C supplementation may have 
a considerable beneﬁ  cial effect; it was 
the results of one of these six trials, 
with schoolchildren in a skiing school 
[4], that particularly impressed Pauling 
[1]. However, great caution should 
be exercised in generalizing from 
this ﬁ  nding, which is based mainly on 
marathon runners.
No beneﬁ  ts have been observed from 
therapeutic use of doses totalling 10 g 
that was divided for the ﬁ  rst three days 
of illness. The equivocal ﬁ  ndings of the 
large study, which used 8 g only on the 
day of onset of respiratory symptoms 
[3], are tantalising and deserve further 
assessment.  
None of the therapeutic trials carried 
out so far has examined the effect of 
vitamin C on children, even though 
the prophylaxis trials have shown 
substantially greater effect on episode 
duration in children.
Study quality for the trials included 
in these three meta-analyses was 
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Figure 1. 500-mg Vitamin C Tablets and Paprikas
Vitamin C was identiﬁ  ed in the 1930s by Albert Szent-Györgyi, 
who received his Nobel Prize partly for this work. He found that 
paprika is a particularly rich source of the vitamin, which made it 
possible to produce kilograms of it for research purposes ([1963] 
Annu Rev Biochem 32: 1–14). Nowadays, the most convenient 
way to increase vitamin C intake is by way of 500-mg tablets, but 
further research is needed to explore the conditions in which 
supplementation may be beneﬁ  cial.PLoS Medicine  |  www.plosmedicine.org 0504
variable, but sensitivity analysis, where 
we excluded studies from the analysis 
that were less adequately blinded 
or randomized, did not change the 
general conclusions of the Cochrane 
Review.  
Future work on this topic should 
explore the value of high dose 
therapy—in particular, in children—
and the mechanisms underlying the 
observed prophylaxis beneﬁ  ts in those 
exposed to substantial physical and/or 
cold stress.  
Text S1. Updated Cochrane Review
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Table 1. Results of the Three Meta-Analyses
Outcome Subgroup Number 
of Trials
Number of 
Participants
Test of 
Heterogeneity a
Magnitude of the Vitamin C Effect 
(95% CI) b
1. Incidence of colds 
during prophylaxis
 29 11,077 p = 0.02, I2 = 38% RR = 0.96 (0.92, 1.00) 
General community 
studies
 23 10,435 p = 0.7, I2 = 0% RR = 0.98 (0.95, 1.00)
Short-term exposure 
to cold and/or severe 
physical stress
 6 642 p = 0.9, I2 = 0% RR = 0.50 (0.38, 0.66) c
2. Duration of colds 
during prophylaxis
 30 9,676 p = 0.15, I2 = 21% RED = −9.7% (−14.1%, −5.4%) c
Children  12 2,434 p = 0.30, I2 = 15% RED = −13.6% (−21.6%, −5.6%) d
Adults  18 7,242 p = 0.19, I2 = 22% RED = −8.0% (−13.1%, −3.0%) d
3. Duration of colds treated 
at the onset of symptoms 
Adults only   7 3,294 p = 0.11, I2 = 42% RED = −2.5% (−10.1%, +5.0%)  
These meta-analyses were of placebo-controlled trials that provided data on incidence and duration of respiratory episodes during continuous oral prophylaxis, or on duration of respiratory episodes following therapy at onset of colds using 
doses in excess of 200 mg of vitamin C.
Prophylaxis indicates vitamin C supplementation over the entire study period. All combined results were pooled using the random effects model. 
a Heterogeneity between trial outcomes in the group: the χ2 test for heterogeneity with p > 0.05 indicates lack of heterogeneity, and the I2 test with I2 = 0% indicates no evidence of heterogeneity, with 100% being the maximum in the I2 scale [5].
b CI, conﬁ  dence interval; RED, relative effect on duration of colds (e.g., if a seven-day cold is shortened by one day, that corresponds to RED = −14% [= −1/7]); RR, relative risk of colds.
c Statistically signiﬁ  cant beneﬁ  t favours those receiving vitamin C with p < 0.0001.
d Statistically signiﬁ  cant beneﬁ  t favours those receiving vitamin C with p < 0.002.
DOI: 10.1371/journal.pmed.0020168.t001
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